Cancer Cachexia Market Size to Reach a CAGR of 3.77% during 2024-2034, Impelled by Advancements in Early Detection

November 20, 2024 | Healthcare

VIEW FULL TABLE OF CONTENTS

Cancer Cachexia Market Outlook 2024-2034:

The cancer cachexia market size is expected to exhibit a growth rate (CAGR) of 3.77% during 2024-2034. The market is driven by numerous encouraging initiatives that are being conducted by the government authorities of various nations and non-governmental organizations (NGOs) to sensitize people about the causes of cancer cachexia and their symptoms. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Advances in Early Detection and Diagnostic Technologies: Driving the Cancer Cachexia Market

Advances in early detection and diagnostic technologies are significantly shaping the cancer cachexia market, addressing a critical need for timely intervention in this debilitating condition. Moreover, technological innovations are enabling earlier and more accurate diagnosis of cachexia. Advanced imaging techniques, such as dual-energy X-ray absorptiometry (DEXA) and computed tomography (CT), are standard for assessing body composition, providing detailed measurements of muscle mass and fat distribution. These tools can detect subtle changes in muscle loss even before significant weight loss occurs, allowing for earlier diagnosis. Additionally, the development of biomarkers is another breakthrough in cachexia diagnostics. Biomarkers like C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) are being used to detect systemic inflammation and metabolic changes associated with cachexia. These markers not only facilitate early detection but also enable personalized treatment approaches by identifying patients at the highest risk. Furthermore, wearable technologies and digital health platforms are also playing a growing role. Devices that monitor physical activity and nutritional intake provide real-time data, helping clinicians track disease progression and patient response to interventions. Mobile health applications empower patients to actively manage their condition, ensuring better adherence to nutritional and therapeutic regimens. As these diagnostic tools become more integrated into clinical practice, they are driving demand for targeted interventions, including pharmacological therapies, nutritional support, and physical rehabilitation programs. Together, these advancements are expanding the cancer cachexia market and improving patient outcomes in this challenging area of oncology.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is a key driver in the expansion of the cancer cachexia market, addressing the urgent need for effective interventions in this debilitating condition. Recent advances in pharmacological research have led to the development of innovative therapies aimed at addressing the multifactorial nature of cachexia. For example, Anamorelin, a ghrelin receptor agonist, has shown promise in improving appetite, increasing lean body mass, and enhancing quality of life in cancer patients. In line with this, selective androgen receptor modulators (SARMs), such as enobosarm, are being investigated for their potential to stimulate muscle growth and improve physical function without the side effects associated with traditional anabolic steroids. Anti-inflammatory agents targeting key cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are also emerging as potential treatments, aiming to reduce the systemic inflammation that contributes to muscle wasting. Additionally, combination therapies integrating anti-catabolic and anabolic agents are being explored to address both muscle degradation and growth simultaneously. Biologic therapies, including monoclonal antibodies, are another promising area of development. These treatments aim to modulate specific molecular pathways involved in cachexia, offering a more precise and targeted approach. These therapeutic advancements not only improve patient outcomes but also contribute to the growth of the cancer cachexia market by expanding treatment options and addressing unmet medical needs.

Marketed Therapies in Cancer Cachexia Market

Anamorelin: Helsinn Therapeutics/Ono Pharmaceutical

Anamorelin is an oral medicine that can aid with various aspects of cancer cachexia, including body weight, appetite, muscle mass, adipose tissue metabolism, energy expenditure, and inflammation. Anamorelin is a ghrelin receptor agonist that activates the growth hormone secretagogue receptor 1a (GHSR). This stimulation leads to the creation of neuropeptide Y (NPY), which enhances hunger.

Emerging Therapies in Cancer Cachexia Market

Ponsegromab: Pfizer

Ponsegromab is an investigational subcutaneous monoclonal antibody designed to treat cancer cachexia. Ponsegromab works by binding to growth differentiation factor-15 in the stomach, inhibiting its interaction with GFRAL in the brain. In a small, open-label, phase Ib research, ponsegromab was related to increased weight, hunger, and physical activity, as well as decreased serum GDF-15 levels, with few side effects.

AV-380: AVEO Pharmaceuticals

AV-380 is an investigational medication being developed by AVEO Pharmaceuticals to treat cancer cachexia. It's an immunoglobulin (Ig) G1 monoclonal antibody that binds to human growth differentiation factor 15, a cytokine involved in cancer-induced cachexia. AV-380 shifts the body's metabolism from breaking down to building up, which helps to relieve cachexia's effects.

Drug Name	Company Name	MOA	ROA
Ponsegromab	Pfizer	Growth differentiation factor 15 inhibitors	Subcutaneous
AV-380	AVEO Pharmaceuticals	Growth differentiation factor 15 inhibitors	Intravenous

Detailed list of emerging therapies in Cancer Cachexia is provided in the final report…

Leading Companies in the Cancer Cachexia Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global cancer cachexia market, several leading companies are at the forefront of developing integrated platforms to enhance the management of cancer cachexia. Some of the major players include Helsinn Therapeutics and Ono Pharmaceutical. These companies are driving innovation in the cancer cachexia market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for the illness.

In April 2021, Ono Pharmaceutical Co., Ltd. announced the launch of Adlumiz (generic name: anamorelin hydrochloride) Tablet 50mg (Adlumiz), a ghrelin receptor agonist, for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer, or colorectal cancer in Japan.

Key Players in Cancer Cachexia Market:

The key players in the Cancer Cachexia market who are in different phases of developing different therapies are Helsinn Therapeutics, Ono Pharmaceutical, Pfizer, AVEO Pharmaceuticals, and Others.

Key Players in Cancer Cachexia Market

Regional Analysis:

The major markets for cancer cachexia include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for cancer cachexia while also representing the biggest market for its treatment. This can be attributed to the increased awareness among healthcare providers, which has led to earlier diagnosis and more proactive management of cachexia, fueling the demand for innovative therapies.

Moreover, advancements in pharmacological treatments are another critical market driver. Novel therapies, such as anamorelin and selective androgen receptor modulators, aim to improve appetite, muscle mass, and physical function. Additionally, anti-inflammatory agents and biologics targeting specific cytokines implicated in cachexia are gaining traction, expanding treatment options.

The robust U.S. healthcare infrastructure supports the adoption of these advanced therapies. Strong investment in research and development, coupled with regulatory incentives like orphan drug designation, accelerates the introduction of new treatments, positioning the U.S. as a leading market for cancer cachexia management.

Recent Developments in Cancer Cachexia Market:

In September 2024, Pfizer Inc. stated its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), fulfilled its primary endpoint of change from baseline in body weight compared to placebo in persons with cancer cachexia and increased levels of GDF-15.

Key information covered in the report.

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cancer cachexia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cancer cachexia market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current cancer cachexia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Cancer Cachexia Market Size to Reach a CAGR of 3.77% during 2024-2034, Impelled by Advancements in Early Detection

Purchase Options New Year Sale

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.